Respiro Diagnostics
Respiro is developing a non-invasive liquid biopsy platform that uses exhaled breath to detect lung cancer and other respiratory diseases.
Respiro Diagnostics has raised €1.2M across 1 funding round from 7 investors, most recently a Pre-Seed round in Jul 2026. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKrespirodiagnostics.com ↗
Total raised
€1.2M
€1,170,480
Funding rounds
1
Investors
7
distinct backers
Active since
2026-07
latest 2026-07
Funding by year
EUR raised per year · 2026 YTDRespiro Diagnostics — funding by year — interactive chart.
Data table
| Respiro Diagnostics — funding by year | |
|---|---|
| 2026 | €1.2M |
Signals
High confidenceRaise-next likelihood15
base rate 24% for Pre-Seed
- ▼ Raised very recently
- ▼ Low backer re-investment
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-08 | Pre-Seed | €1.2M | Amadeus Capital Partners,Conception X Angel Syndicate,Innovate UK,KQ Labs,SFC Capital,strategic angel investors+1 more | View deal → |
Investors
7Amadeus Capital PartnersConception X Angel SyndicateInnovate UKKQ LabsSFC Capitalstrategic angel investorsZinc
Related news
Similar companies
same sector or countryGlobal coverage: FundingData